{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:54:28Z","timestamp":1783774468300,"version":"3.55.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n \n Since 2018, the TAILORx and RxPONDER trials have demonstrated that the 21-gene recurrence score (RS) can be indicative of the benefit of adjuvant chemotherapy in hormone receptor (HR)\u2013positive,\n ERBB2<\/jats:italic>\n (formerly\n HER2<\/jats:italic>\n )\u2013negative breast cancer with 3 or fewer positive lymph nodes. However, its applicability to key subgroups with high risk for recurrence, including premenopausal women with positive lymph nodes and racial and ethnic minority individuals, remains unclear.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To assess the temporal patterns of and disparities in adjuvant chemotherapy use in early-stage HR-positive,\n ERBB2<\/jats:italic>\n -negative breast cancer by age, genomic risk, and nodal involvement.\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This retrospective cohort study analyzed clinical data from the 2010 to 2022 National Cancer Database. The cohort included women with stage I to III, HR-positive,\n ERBB2<\/jats:italic>\n -negative breast cancer who had undergone a lumpectomy or mastectomy and were eligible for endocrine therapy. Patients were categorized into premenopausal (aged \u226450 years) or postmenopausal (aged &amp;gt;50 years) status. Nodal status (negative or positive) was pathologically confirmed. RS was classified per the TAILORx trial, with RS of 0 to 10 as low genomic risk, RS of 11 to 25 as intermediate genomic risk, and RS of 26 or higher as high genomic risk. Data were analyzed from January 20 to August 11, 2025.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Adjuvant systemic therapy, defined as receipt of either endocrine therapy alone or chemoendocrine therapy (chemotherapy plus endocrine therapy), after surgery (lumpectomy or mastectomy).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 504\u202f937 women (mean [SD] age, 60.0 [10.7] years; 5.4% Hispanic, 4.3% non-Hispanic Asian or Pacific Islander, 8.1% non-Hispanic Black, 81.3% non-Hispanic White, and 0.9% other race or ethnicity) were included. Among premenopausal patients with node-negative tumors, adjuvant chemotherapy use decreased from 6.5% in 2010 to 0.9% in 2022 for those with low genomic risk and from 29.6% in 2010 to 11.1% in 2022 for those with intermediate genomic risk. However, among premenopausal patients with node-positive disease, chemotherapy use declined from 33.3% in 2010 to 12.7% in 2019 but increased to 25.7% in 2022 for the low genomic risk group. For the intermediate genomic risk group, chemotherapy use declined from 55.8% in 2010 to 38.1% in 2019 but increased to 48.9% in 2022. Among postmenopausal women, chemotherapy use for those with low to intermediate genomic risk continued to decrease from 2010 to 2022 in both node-negative and node-positive disease status. Black women with high genomic risk had lower odds of chemotherapy receipt than White women, regardless of menopausal or nodal status (adjusted odds ratio [AOR], 0.84; 95% CI, 0.78-0.90). Premenopausal Black women with low to intermediate genomic risk also had lower odds of chemotherapy receipt than White women (AOR, 0.85; 95% CI, 0.77-0.94), regardless of nodal status.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n This retrospective cohort study found that adjuvant chemotherapy use almost doubled in premenopausal patients with node-positive tumors and with a low to intermediate genomic risk from 2019 to 2022 but decreased for patients with node-negative disease, coinciding with the publication of the TAILORx and RxPONDER trials. The findings highlight the variability in genomic assay use to facilitate adjuvant therapy recommendations for HR-positive,\n ERBB2<\/jats:italic>\n -negative breast cancer.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.49109","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:00:34Z","timestamp":1766505634000},"page":"e2549109","source":"Crossref","is-referenced-by-count":5,"title":["Adjuvant Chemotherapy Use for Hormone Receptor\u2013Positive,\n ERBB2<\/i>\n -Negative Breast Cancer After RxPONDER Trial"],"prefix":"10.1001","volume":"8","author":[{"given":"Jincong Q.","family":"Freeman","sequence":"first","affiliation":[{"name":"Department of Public Health Sciences, The University of Chicago, Chicago, Illinois"},{"name":"Cancer Prevention and Control Research Program, UChicago Medicine Comprehensive Cancer Center, Chicago, Illinois"},{"name":"Center for Health and the Social Sciences, The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poornima","family":"Saha","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Endeavor Health, Evanston, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Peiffer","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Shubeck","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Chicago Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha R.","family":"Yarlagadda","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezheng","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, The University of Chicago, Chicago, Illinois"},{"name":"Cancer Prevention and Control Research Program, UChicago Medicine Comprehensive Cancer Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick M.","family":"Howard","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"1","key":"zoi251320r1","first-page":"12","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"zoi251320r2","first-page":"477","article-title":"Breast cancer statistics 2024.","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"zoi251320r3","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/annonc\/mdq683","article-title":"Long-term toxic effects of adjuvant chemotherapy in breast cancer.","volume":"22","author":"Azim","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi251320r4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41523-022-00489-9","article-title":"Toxicity index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology\/NSABP B-30.","volume":"8","author":"Henry","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"zoi251320r5","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/cncr.21464","article-title":"The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.","volume":"104","author":"Oestreicher","year":"2005","journal-title":"Cancer"},{"issue":"22","key":"zoi251320r6","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1002\/cncr.30274","article-title":"Estimating regimen-specific costs of chemotherapy for breast cancer: observational cohort study.","volume":"122","author":"Giordano","year":"2016","journal-title":"Cancer"},{"issue":"27","key":"zoi251320r7","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi251320r8","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi251320r9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi251320r10","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer.","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi251320r11","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer.","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"zoi251320r12","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-dependent relationship between young age at diagnosis and breast cancer survival.","volume":"34","author":"Partridge","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi251320r13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamaoncol.2020.7320","article-title":"Association of race\/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women.","volume":"7","author":"Hoskins","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"zoi251320r14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaoncol.2025.0178","article-title":"Prognostic and predictive insights from genomic assays for breast cancer in diverse populations: a review.","volume":"11","author":"Abdou","year":"2025","journal-title":"JAMA Oncol"},{"issue":"17","key":"zoi251320r15","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1002\/cncr.32956","article-title":"Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.","volume":"126","author":"Ibraheem","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"zoi251320r16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/bjs.11401","article-title":"Breast cancer in young black women.","volume":"107","author":"Walsh","year":"2020","journal-title":"Br J Surg"},{"key":"zoi251320r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102887","article-title":"Current controversies in the use of Oncotype DX in early breast cancer.","volume":"135","author":"Berton Giachetti","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"zoi251320r19","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1245\/s10434-019-07213-1","article-title":"Incident cases captured in the National Cancer Database compared with those in U.S. population based central cancer registries in 2012-2014.","volume":"26","author":"Mallin","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"zoi251320r20","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the National Cancer Database for outcomes research: a review.","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"issue":"8","key":"zoi251320r21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi251320r24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13058-021-01453-4","article-title":"Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use.","volume":"23","author":"Schaafsma","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"1","key":"zoi251320r26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41523-024-00651-5","article-title":"Development and validation of a clinical breast cancer tool for accurate prediction of recurrence.","volume":"10","author":"Dhungana","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"zoi251320r27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1946","article-title":"Machine learning-based prediction of distant recurrence risk and ribociclib treatment effect in HR+\/HER2- early breast cancer using real-world and NATALEE data.","author":"Howard","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"28","key":"zoi251320r28","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1200\/JCO-25-00742","article-title":"Identifying patients with low relapse rate despite high-risk estrogen receptor-positive\/human epidermal growth factor receptor 2-negative early breast cancer: development and validation of a clinicopathologic assay.","volume":"43","author":"Bidard","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi251320r30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.9449","article-title":"Declination of treatment, racial and ethnic disparity, and overall survival in US patients with breast cancer.","volume":"7","author":"Freeman","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi251320r31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00011","article-title":"Cognitive bias: the downside of shared decision making.","volume":"2","author":"Ozdemir","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"issue":"12","key":"zoi251320r32","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1080\/0284186X.2017.1374555","article-title":"Preferences and actual chemotherapy decision-making in the greater plains collaborative breast cancer study.","volume":"56","author":"Berger","year":"2017","journal-title":"Acta Oncol"},{"key":"zoi251320r33","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.2147\/PPA.S432821","article-title":"Understanding patient preferences regarding the important determinants of breast cancer treatment: a narrative scoping review.","volume":"17","author":"Yeo","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"zoi251320r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.002","article-title":"Impact of anthracyclines in genomic high-risk, node-negative, HR-positive\/HER2-negative breast cancer.","author":"Chen","year":"2025","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi251320r35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1200\/JCO.23.01428","article-title":"Long-term follow-up of the anthracyclines in early breast cancer trials (USOR 06-090, NSABP B-46-I\/USOR 07132, and NSABP B-49 [NRG Oncology]).","volume":"42","author":"Geyer","year":"2024","journal-title":"J Clin Oncol"},{"key":"zoi251320r18","unstructured":"American College of Surgeons. National Cancer Database. Accessed July 24, 2022. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/"},{"key":"zoi251320r22","unstructured":"NCCN Guidelines for Breast Cancer, Version 4.2025. National Comprehensive Cancer Network. Accessed May 16, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"zoi251320r23","unstructured":"US Census Bureau. American Community Survey data. Accessed May 17, 2025. https:\/\/www.census.gov\/programs-surveys\/acs\/data.html"},{"key":"zoi251320r25","doi-asserted-by":"crossref","unstructured":"Evaluating the addition of adjuvant chemotherapy to ovarian function suppression plus endocrine therapy in premenopausal patients with pN0-1, ER-positive\/HER2-negative breast cancer and an oncotype recurrence score less than or equal to 25 (OFSET). ClinicalTrials.gov identifier: NCT05879926. Accessed May 9, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05879926?term=BR009&checkSpell=false&rank=3#study-overview","DOI":"10.1158\/1538-7445.SABCS23-PO2-19-02"},{"key":"zoi251320r29","doi-asserted-by":"crossref","unstructured":"Shamai? G, Cohen? S, Binenbaum? Y, . Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit.? medRxiv. Preprint posted online May 16, 2025. doi:10.1101\/2025.05.15.25327686?","DOI":"10.1101\/2025.05.15.25327686"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2843146\/freeman_2025_oi_251320_1765908835.1644.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:00:36Z","timestamp":1766505636000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2843146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.49109","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]}}}